Selection of DNA aptamers for ovarian cancer biomarker HE4 using CE-SELEX and high-throughput sequencing

Rachel M. Eaton · Jamie A. Shallcross · Liora E. Mael · Kepler S. Mears · Lisa Minkoff · Delia J. Scoville · Rebecca J. Whelan

Received: 1 February 2015 / Revised: 25 March 2015 / Accepted: 26 March 2015 / Published online: 12 April 2015
© The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract The development of novel affinity probes for cancer biomarkers may enable powerful improvements in analytical methods for detecting and treating cancer. In this report, we describe our use of capillary electrophoresis (CE) as the separation mechanism in the process of selecting DNA aptamers with affinity for the ovarian cancer biomarker HE4. Rather than the conventional use of cloning and sequencing as the last step in the aptamer selection process, we used high-throughput sequencing on an Illumina platform. This data-rich approach, combined with a bioinformatics pipeline based on freely available computational tools, enabled the entirety of the selection process—and not only its endpoint—to be characterized. Affinity probe CE and fluorescence anisotropy assays demonstrate the binding affinity of a set of aptamer candidates identified through this bioinformatics approach.

Keywords Aptamer · CE-SELEX · HE4 · Ovarian cancer · Biomarker · High-throughput sequencing

Introduction

The long-term survival of ovarian cancer patients correlates strongly with stage at diagnosis. Local disease, confined to one or both ovaries, responds well to existing treatments, with 5-year survival rates averaging 92 % [1]. By contrast, the 5-year survival rate for patients with metastatic cancer at distant sites is 27 %. These data—and the fact that most ovarian cancers are not diagnosed until metastasis has occurred—provide compelling motivation for the discovery and validation of new ovarian cancer biomarkers that may enable earlier detection.

Using comparative hybridization assays on an array of 21, 500 ovarian cDNAs, Hood and coworkers identified the HE4 (WFDC2) gene as more highly expressed in ovarian cancer tissue than in noncancerous ovarian epithelium [2]. This observation was supported by serial analysis of gene expression, which also found HE4 to be amplified in ovarian cancer [3]. A 2003 study demonstrated that serum HE4 protein is detectable via double-determinant immunoassay and is an ovarian cancer biomarker with sensitivity and specificity comparable to that of CA125, the clinical "gold standard," but with the likely advantage of lower false-positive rates in patients with benign disease [4]. Thorough characterization of protein expression in various tissue types via immunostaining confirmed that normal ovarian epithelium does not express HE4, whereas the protein is strongly expressed on serous and endometrioid tumors, which together constitute the vast majority of ovarian cancer cases [5, 6]. In 2008, the FDA approved the use of a serum HE4 assay for monitoring recurrence in patients with epithelial ovarian cancer. The combination of HE4 and CA125, when used in the Risk of Ovarian Malignancy Algorithm (ROMA) test, is effective at classifying women presenting with a pelvic mass into high- or low-risk categories, which enables the triage of women likely to have ovarian cancer to clinical settings and surgeons with appropriate expertise [7, 8]. The FDA approved this use of ROMA in 2011. Most relevant to the challenge of early detection are the results of ELISA assays performed on banked serum samples collected 1 to 18 years prior to ovarian cancer diagnosis [9]. That study
showed the mean concentrations of HE4 (along with serum markers CA125 and mesothelin) in serum samples from cancer patients began to visually increase 3 years before diagnosis, reaching detectable levels 1 year before clinical presentation [9]. Novel analytical approaches to HE4 detection may therefore contribute to early detection of ovarian cancer and associated improvement in patient outcomes.

To complement existing antibody-based detection strategies, many investigators have explored the use of nucleic acid aptamers [10, 11] as affinity probes. Aptamers share with antibodies the property of high-affinity and high-selectivity binding to a target of interest, while having distinct benefits over antibodies in their greater ease of labeling and facile regeneration of native confirmation upon heat cycling. Along with their entirely in vitro development process—the use of animals or cells is not required—these attributes have made aptamers an attractive recognition element employed in a variety of analytical applications [12–14]. Various modes of aptamer selection, referred to as Systematic Evolution of Ligands by EXponential enrichment (SELEX), have been developed [15, 16]. Briefly, a randomized “library” of oligonucleotides is subject to iterative cycles of (1) incubation with the target, (2) separation to resolve bound oligos from unbound, and (3) amplification to reproduce those oligos possessing desired binding attributes. In our development of DNA aptamers with affinity for HE4, we used a capillary electrophoresis (CE)-based separation mechanism [17, 18]. Owing to the high applied field strength used in CE separations, CE-SELEX enables efficient separation of bound and unbound oligos. This selection method has been shown to converge the unselected library onto functional aptamers in fewer rounds than selection methods based on column chromatography or nitrocellulose filtration [19].

Traditionally, the final stage of the aptamer selection process has been to clone the selected oligonucleotide pool into a bacterial expression system, sequence these oligos by Sanger methods, and characterize the affinity of the identified sequences for the target. It has been shown, however, that such approaches can fail to identify high-affinity aptamers [20]. The recent proliferation of high-throughput sequencing (HTS) techniques, also known as next-generation sequencing, deep sequencing, or massively parallel sequencing [21, 22], has made it possible to sequence pools of aptamer candidate oligos with significantly greater coverage than a clone-and-sequencing approach. HTS enables the full evolutionary path of the SELEX process to be characterized, not only its endpoint [23]. As a result, better aptamers can be selected with fewer rounds of selection [24], even in a single round [25], by removing the need for the pool to fully converge on a consensus sequence or sequences. Advantages of this approach include reducing time and materials required and minimizing the opportunities for the introduction of polymerase chain reaction artifacts [26] that can bias selection, ultimately causing the loss of high-affinity binders [27]. Similarly, sequences identified by their fold enrichment, rather than raw read counts, can locate high-affinity binders that traditional Sanger sequencing can miss [20]. HTS can also reduce the number of sequences needing to be tested in vitro, when coupled with bioinformatics, by identifying clusters of oligos with a common sequence or structure [28]. A novel method of aptamer affinity determination, MPBind [29], uses a statistical analysis of HTS data to determine aptamer affinity and may prove valuable to users in this field.

Here, we report on our use of CE-SELEX to identify DNA aptamers with affinity for the ovarian cancer marker HE4. Selected DNA was subject to HTS on the Illumina platform. Enrichment and clustering analysis were performed in-house to identify the most promising candidate aptamers for in vitro affinity characterization.

Experimental

Reagents

Oligonucleotides—including unselected DNA library, polymerase chain reaction (PCR) and sequencing primers, and labeled aptamers for in vitro testing—were purchased from Integrated DNA Technologies (Coralville, IA). The sequences, previously reported by Bowser and coworkers [23] were forward primer 5′-FAM-AGC ACA GAG GTC AGA TG-3′, reverse primer 5′-biotin-TTC ACG GTA GCA CGC ATA GG-3′, and single-stranded DNA (ssDNA) library 5′-FAM-AGC ACA GAG GTC AGA TG (N)25 CCT ATG CGT GCT ACC GTG AA-3′. Nuclease-free water, 25 mM MgCl2, 5.0 U/μL Taq polymerase (for PCR), and Blue/Orange 6× loading dye (for gel loading) were purchased from Promega (Madison, WI). Deoxyribonucleotide triphosphates (dNTPs, 10 mM stock) were obtained from QIAGEN, Inc. (Valencia, CA). NuSieve GTG agarose was purchased from Cambrex BioScience (Rockland, ME). 5× Tris Borate EDTA (TBE) was made from TRIZMA Base and boric acid purchased from Sigma (St. Louis, MO), and 0.5 M EDTA (OmniPur; Gibbstown, NJ). The buffer used for aptamer selection and CE separation was 25 mM Tris, 192 mM glycine, 5 mM KH2PO4, pH 8.3 (TGK) prepared from Thermo Scientific Tris-Glycine powder (Asheville, NC), and KH2PO4 from Mallinckrodt Chemical Works (St. Louis, MO) using 18.2 MΩ cm water as a diluent. Streptavidin-agarose was purchased from Thermo Scientific Pierce Biotechnology Inc. (Rockford, IL). Bio-Rad columns were purchased from Bio-Rad Technologies (Hercules, CA). Binding and washing (B&W) buffer (10 mM Tris, 2 mM NaCl, 1 mM EDTA at pH 7.6, 2× concentration) was made from NaCl purchased from VWR (Bridgeport, NJ). Absolute ethanol was sourced from AAPER Alcohol and Chemical Co. (Shelbyville, KY).
Human recombinant HE4 protein with a glutathione-S-transferase purification tag (HE4-GST), GST protein, and the storage buffer for both proteins (50 mM Tris-HCl containing 10 mM reduced glutathione, pH 8.0) were purchased from Abnova (Taipei, Taiwan).

Capillary electrophoresis and aptamer selection

Capillary electrophoresis aptamer selection was performed on a Beckman Coulter P/ACE MDQ system (Fullerton, CA) with exchangeable UV absorbance and laser-induced fluorescence (LIF) detectors (488 nm excitation, 520 emission). The capillary was 51.3 cm in length and 42.5 cm from inlet to window, with an inner diameter of 50 μm and an outer diameter of 360 μm (Polymicro Technologies Inc., Phoenix, AZ).

Before incubation with target protein, DNA was heated to 95 °C for 3 min and cooled on ice. For each selection round, DNA, target protein, and TGK buffer were combined in 10 μL total volume. The mixture was incubated at 25 °C for 30 min. The equilibrated sample was injected (2 psi for 5 s) and separated (25 kV). LIF detection was used to monitor the separation. During a positive selection round, the eluate was collected into 48 μL TGK buffer. In a negative selection round, unbound DNA was also eluted into 48 μL TGK buffer. The injection, separation, and collection process was repeated.

Table 1 Incubation conditions used during rounds of aptamer selection

| Round | Pos/neg | Target | [Target] | DNA source | [DNA] |
|-------|---------|--------|----------|------------|-------|
| R1    | Pos     | HE4-GST| 50 nM    | Library    | 10 μM |
| R2+   | Pos     | HE4-GST| 10 nM    | R1         | 50 nM |
| R2−   | Neg     | GST    | 50 nM    | R2+        | 150 nM|
| R3+   | Pos     | HE4-GST| 5 nM     | R2−        | 150 nM|
| R3−   | Neg     | GST    | 25 nM    | R3+        | 200 nM|
| R4    | Pos     | HE4-GST| 1 nM     | R3−        | 300 nM|
| R5    | Pos     | HE4-GST| 0.5 nM   | R4         | 300 nM|

Selected DNA involved two steps: determination of optimal cycle number and preparative PCR. Master mix was made by combining 484 μL nuclease-free water, 16 μL dNTPs, 20 μL each of forward and reverse primers, 96 μL MgCl₂, and 160 μL colorless 6× buffer. After mixing, 149.25 μL of the master mix was removed and combined with 0.75 μL Taq polymerase. To 94.5 μL of this completed master mix we added 5.5 μL of DNA collected during selection. This mixed solution was divided equally over thin-walled tubes that were subject to PCR for different numbers of cycles, where each cycle involved three steps: denaturing (95 °C, 30 s), annealing (53 °C, 15 s), and extension (72 °C, 15 s). The samples, which contained different amounts of amplified product, were resolved on a 4 % agarose gel at an applied voltage of 85 V. Gels were imaged on a Kodak Gel Logic 200 Integrated Illumination Cabinet and Imaging System, and photos were digitally improved using Kodak Molecular Imaging software, version 4.5 (Rochester, NY). The fluorescence of forward primers and amplified product enabled visualization of DNA without ethidium bromide staining. The number of cycles that yielded a visible product band with minimal primer and no by-products was used for preparative PCR. In preparative PCR, 646.75 μL of master mix was combined with 3.25 μL Taq polymerase. Seventy microliters of this completed master mix was combined with 5.5 μL of collected DNA in eight separate vials. Completed master mix without added DNA was run as a negative control. After completing the optimal number of PCR cycles, 10 μL of each sample and the control were visualized on a 4 % agarose gel to confirm yield and purity. Remaining samples were pooled and subject to single stranded.

Single stranding

Double-stranded PCR product was converted to single-stranded DNA using streptavidin columns. For the single-stranding process, 300 μL of streptavidin-agarose slurry was placed in a Bio-Rad chromatography column and washed five times with 500-μL portions of 2× B&W buffer. Pooled PCR product was loaded onto the column with an equal volume of 2× B&W buffer, and the mixture was allowed to incubate at room temperature with gentle vortexing every 5 min for 30 min. The column was then washed ten times, with the following buffers, in order of decreasing ionic strength: four washes with 550 μL 2× B&W buffer; five washes with 550 μL 1× B&W buffer; and one wash with 500 μL ultrapure H₂O. Thirty micromoles of NaOH (200 μL of 0.15 M NaOH) was then added to the column, gently vortexed, and incubated at 37 °C for 10 min to denature double-stranded DNA (dsDNA). The column was then gently vortexed and the unretained ssDNA (containing the FAM forward primer) eluted into 30 μmol of acetic acid (200 μL of 0.15 M acetic acid) to neutralize the hydroxide. The solution was buffered...
by the addition of 40 μL of 3 M sodium acetate, followed by 1000 μL of cold 100 % ethanol to precipitate ssDNA. The NaOH elution process was repeated into a separate collection tube, and the two samples (containing ssDNA in ethanol) were incubated at −20 °C or on wet ice for at least 2 h but not more than 12 h. The two portions of eluted DNA were centrifuged at 13,200 RPM for 45 min at 4 °C. Supernatant was pipetted from each tube, leaving 100 μL DNA-containing solution. One milliliter of cold 70 % ethanol was added to both tubes. After 20 min of spinning at 4 °C, supernatant was removed, leaving 50 μL. The cold ethanol washing process was repeated; after centrifugation, supernatant was carefully removed, leaving 25 μL. Both portions of eluted DNA were then dried in a Speedvac at medium heat for 10 min, followed by 5 min spinning at room temperature. Each tube was then reconstituted in 15 μL of TGK buffer. The DNA was then combined and divided as follows: 10 μL was archived for sequencing, 10 μL was archived for NanoDrop and bulk affinity measurements, and 10 μL was used for the next round of selection.

Sequencing and bioinformatics

After aptamer selection was complete, DNA collected from each round was amplified using Illumina sequencing primers. Archived DNA from each round was diluted to 100 nM using ultrapure water. Each sample was assigned a unique reverse primer containing the index used for barcoding. Master mix containing all PCR reagents except Taq polymerase and the reverse primers was made from 563 μL nuclease-free water, 18 μL dNTPs, 22 μL forward primer, 108 μL MgCl₂, and 180 μL colorless buffer. To 97 μL of this mix was added 0.5 μL of Taq polymerase and 2.4 μL of the specific reverse primer. Seventy-four microliters of this mixed solution was added to 1 μL DNA solution; samples and controls were amplified by PCR using an optimized cycle number. PCR products were imaged on a 3 % agarose gel containing 1 μg/mL ethidium bromide to confirm yield and the absence of contaminants or by-products. Samples were sequenced at the University of Wisconsin Biotechnology Center DNA Sequencing Facility.

Bioinformatic screening of the sequenced DNA used a data pipeline based on freely available software, with the exception of enrichment analysis, which used a Python program written in-house. This program (enrichment.py) has been made available on GitHub at https://github.com/rebeccawhelan/PythonEnrichment. After a preliminary analysis of the FastQC files to ensure the sequencing was successful, data were sent into a Biopieces pipeline. Each round’s data was individually read into the pipeline using read_fastqc. Selection primers were removed with remove_primers, using a 5 % mismatch tolerance and a 0 % tolerance for insertions and deletions. All bases beyond the reverse sequence primer (i.e., adaptors and sequencing primers) were removed in this step. These sequences were then filtered using grab to select only sequences with a length of 25±2. These data were processed with uniq_seq, creating one record for each sequence with associated count information. The records were sorted by read count in descending order using sort_records and written to a file as tabular data.

Affinity probe capillary electrophoresis

Affinity probe capillary electrophoresis affinity assays were performed using a Beckman P/ACE MDQ (Beckman Coulter, Fullerton, CA) equipped with an argon-ion laser. An unmodified fused silica capillary (Polymicro Technologies, Phoenix, AZ; ID=50 μm, OD=360 μm, total length=49.5 cm, length from inlet to detector=39.6 cm) was held at 25 °C. Samples were injected from the outlet end, and negative polarity was applied to minimize the distance from injection to detection (length to detector=9.9 cm). Each sample contained 10 nM FAM-labeled aptamer (synthesized as a 25mer sequence without primer regions), 20 nM fluorescein (internal standard), and 1 mg/mL BSA. TGK was used both as the diluent in sample preparation and as the electrophoresis buffer. To prepare samples, a bulk solution of aptamer in TGK was heated to 90 °C for 3 min, and then put on ice to cool. Fluorescein and bovine serum albumin (BSA) were then added, and the solution was distributed over an appropriate number of sample tubes. Finally, protein (HE4-GST or GST, in separate experiments) was added to a sequence identity threshold of 0.8 and assigned to clusters by the highest identity across all clusters.

 Springer
free DNA aptamer peak, relative to the internal standard, was used to indicate the complex formation between aptamer and protein. Data were fit with an isotherm equation:

\[
\text{Ratioed peak height} = \frac{\text{constant}}{1 + \left(\frac{K_d}{T + 0.5 \times (A + T + K_d - \left(\frac{(A + T + K_d)^2 - 4 \times A \times T}{0.5}\right))}\right)}
\]

where \( T \) is protein concentration (varied) and \( A \) is aptamer concentration (constant, typically 10 nM), using IgorPro (v. 6.12) graphing software.

**Fluorescence anisotropy**

Fluorescence anisotropy was measured using a SpectraMax M5 multimode plate reader with polarizing optics (Molecular Devices, Sunnyvale, CA). Tested aptamers were ordered from Integrated DNA Technologies, Inc. (Coralville, IA) with a 5’ TEX615 (Texas Red) fluorophore. One hundred nanomolar DNA aptamer in buffer (TGK) was heated to 95 °C for 3 min, cooled to 4 °C, then allowed to warm to room temperature. Heat-cycled DNA solution was combined with HE4-GST at a range of final concentrations from 0 to 750 nM in the presence of 0.1 mg/mL bovine serum albumin (BSA). The volume of protein plus protein buffer was constant across all samples. After incubating for at least 30 min in the dark at 25 °C, samples were loaded in duplicate (70 μL/well) into a 96-well Fluotrac 200 black immunology plate (USA Scientific, Ocala, FL) and analyzed in the SpectraMax, with temperature held at 25 °C. The \( \lambda_{ex} \) for fluorescence anisotropy was 585 nm, \( \lambda_{em} \) was 635 nm, and the wavelength cut-off was 610 nm. Raw data (fluorescence emission parallel and perpendicular to the excitation) were blank-corrected before the anisotropy values were calculated. Measurements were run at least in duplicate and fit with an isotherm function:

\[
r - r_0 = \frac{\text{constant}}{1 + \left(\frac{K_d}{T + 0.5 \times (A + T + K_d - \left(\frac{(A + T + K_d)^2 - 4 \times A \times T}{0.5}\right))}\right)}
\]

where \( T \) is protein concentration (varied), \( A \) is aptamer concentration (constant), \( r \) is the anisotropy measured in the presence of protein, and \( r_0 \) is the anisotropy in the absence of protein, using IgorPro (v. 6.12) graphing software.

**Results and discussion**

An unselected DNA library with \( N=25 \) random region was used as the input to the selection process because it provided a good balance of sequence diversity, coverage, and computational tractability. Assuming that each base is equally likely to appear at each position in the random region, there are \( 4^{25} \) (~1 × 10\(^{15}\)) possible sequences in such a library. In our selection, we used 100 pmol (~6 × 10\(^{13}\) molecules) of DNA as the initial input, giving any individual sequence an expected abundance of 0.05 (a library with \( N=23 \) would give an expected abundance of 1). Using a longer random region would result in lower coverage of sequence space that could result in the loss of useful motifs, whereas a shorter random region might lack the complexity to form relevant secondary and tertiary structures involved in target binding.

Table 1 shows the conditions used in our CE-SELEX process. Each incubation condition was completed once, in the order shown (R1 to R5). Positive selection rounds involved incubating DNA oligonucleotides (either unselected library or single-stranded DNA from a previous selection round) with HE4-GST. Nonequilibrium separation conditions were applied to pre-equilibrated mixtures, as is common in capillary-based aptamer selection. At the pH of our capillary-based aptamer selection. The protein target of interest (HE4) was covalently attached to a purification tag (GST). To avoid selecting aptamers with affinity for GST, we included two rounds of negative selection, in which GST was the protein target and only the unbound DNA—comprising those oligos without affinity for GST—was collected. DNA collected from each selection round was then amplified by PCR to an optimal number of cycles and single stranded to generate the ssDNA for the next selection round. Figure 1 demonstrates the sensitivity of the product to the number of rounds of PCR conducted. Insufficient rounds of PCR mean that the product
of interest is not formed, but too many rounds of PCR result in the consumption of the dsDNA product of interest and the formation of by-products. The sensitivity of PCR when amplifying aptamers has been thoroughly described by Krylov’s group \[26\]; we include a cycle-determining step in each SELEX round and amplify selected DNA to the optimal cycle number to avoid this problem. In the cycle-determining step, identically prepared samples were subjected to different numbers of PCR cycles. These samples were resolved in parallel lanes on an unstained agarose gel and imaged on a UV illuminator through the excitation of the fluorescein primer. The optimal cycle number was the number of PCR cycles that gave a clearly visible band of the desired dsDNA product, but for which no by-products were visible on the gel.

The bioinformatics pipeline used after the completion of the CE-SELEX process is illustrated in Fig. 2. DNA archived after each selection round was sequenced on an Illumina platform. Information about the resulting sequence data is shown in Table 2. The number of oligo sequences yielded by this next-generation sequencing technique is significantly larger (max = 10.1 × 10^6; min = 2.7 × 10^6; average = 6.4 × 10^6) than what would typically be achievable with a clone-and-sequence approach. Sequence duplication, reported as a percent, is the number of duplicate sequences relative to unique. Two trends are notable from the data in Table 2. First, there is duplication of sequences in the ostensibly random—unselected library (R0). We believe that this phenomenon may result from a combination of errors occurring during synthesis and sequencing. We have observed a strong bias for thymine in ostensibly random libraries (data not shown), suggesting synthesis bias. In addition, the majority of sequence duplication appears to result from contamination by the Illumina sequence adaptor. Second, the percent duplicated sequences increases during the selection process, from around 10 % in the unselected library DNA to around 40 % after the fifth round of selection. We interpret these data to mean that although the unselected library is not composed of a random population of unique DNA sequences—as is often assumed in SELEX—the selection process nonetheless substantially modifies the DNA pool. DNA collected from two rounds of negative selection were also sequenced and served as a negative control in the bioinformatics analysis. Certain sequences that were abundant in the unselected oligo library persisted through multiple rounds of selection. These sequences were abundant in both positive and negative sequence pools, indicating that they are parasitic, rather than truly selected. Sequences with high fold

Table 2 Characteristics of data resulting from Illumina sequencing

| SELEX round | DNA sequenced | Number of reads | Sequence duplication |
|-------------|---------------|----------------|---------------------|
| R0          | Free          | 6.7 × 10^6     | 11.8 %              |
| R1          | Bound         | 3.8 × 10^6     | 13.0 %              |
| R2+         | Bound         | 2.7 × 10^6     | 14.0 %              |
| R2–         | Bound         | 8.4 × 10^6     | 12.4 %              |
| R3+         | Bound         | 6.4 × 10^6     | 14.0 %              |
| R3–         | Bound         | 5.3 × 10^6     | 20.0 %              |
| R3–         | Free          | 6.2 × 10^6     | 14.0 %              |
| R4          | Bound         | 8.0 × 10^6     | 24.1 %              |
| R5          | Bound         | 10.1 × 10^6    | 37.7 %              |

SELEX round numbers are as described in Table 1. The unselected library is designated “R0″
enrichment and cluster abundance were generally not found in negative selection pools; therefore, we were able, through bioinformatics analysis, to filter out these parasitic sequences in silico. MPBind was used to assess possible binding potentials. It was trained using all five rounds of positive selection and used to calculate $Z$-scores for several highly enriched potential aptamers. Four promising aptamer sequences were chosen for testing. We chose sequences that were enriched during the selection process and were representative of large clusters. A control sequence was also identified that showed little change in abundance between the unselected pool and the selection rounds. Table 3 shows the sequences that were selected for in vitro characterization. Sequence A1 was the most enriched sequence in R5, and it scores moderately well in sequence-based clustering. It does not appear in any of the negative selection rounds, nor does it have any homologs in the library (defined as having a greater than 85% sequence identity with a sequence at $\geq 5$ counts in the unselected library). In addition, it scores well in MPBind ($Z$-score = 10.75). Sequence A3 is the third most enriched sequence in R5. Although slightly less enriched than A1, it belongs to the largest sequence cluster. It shares sequence homology with an overrepresented library sequence, but achieving this alignment requires numerous indels and mismatches that are not likely to have resulted from PCR or sequencing error alone. Possibly due to this homology, however, this sequence ranks poorly under MPBind with a $Z$-score of $-7.06$. Sequence B10 is the second most enriched sequence by R4. It appears in the largest sequence-based cluster in that round, with no library homologs or counts in the negative selection; it has a $Z$-score of $-2.08$. Unlike the other aptamer sequences tested, B10 is 26 bases long; our bioinformatics analysis was designed to include all sequences of length $25 \pm 2$. This 26mer sequence is possibly an artifact of PCR or synthesis error, but we chose to study it because of its high degree of enrichment. D3 is the most enriched sequence in R2; it does not appear in the negative selection rounds, and it has a moderately positive $Z$-score (1.6). Finally, L1 was chosen as a negative control. It was the most abundant sequence in the unselected library and subsequent rounds, enabling us to test the hypothesis that a sequence that is initially abundant may still bind to the protein target. However, the sequence of L1 overlaps significantly with the Illumina index adapter, suggesting that it might be a contamination introduced post-SELEX.

Two orthogonal techniques—fluorescence anisotropy and affinity probe capillary electrophoresis—were used to characterize the binding of each aptamer candidate for the positive

| ID | Round | Rank | Enrichment | Sequence | $Z$-score | Cluster size |
|----|-------|------|------------|----------|-----------|-------------|
| A1 | 5     | 1    | 26         | TTATCGTAGACAGTCTACCATCCTACAC | 10.75     | 14          |
| A3 | 5     | 3    | 22         | CACAGTGCTACATTAGGCGATTACGTC | $-7.06$   | 46          |
| B10| 4     | 10   | 14         | CAGTGCGCTTTATGGCGTAGGTC     | $-2.08$   | 18          |
| D3 | 2     | 3    | 12         | ATGGTCGCAAAGAAGTTTACAGGAG    | 1.6       | 10          |
| L1 | 0     | 1    | 1          | CCGTCTTCTTGCGGAAAAAAA       | $-15.9$   | n/a         |

$n/a$ not available
selection protein target (HE4-GST). Figure 3 shows a representative binding isotherm, for the aptamer A3, collected with affinity probe CE, with increasing concentrations of HE-GST. On the y-axis is plotted the height of the free DNA peak in the absence of protein relative to the DNA peak in the presence of protein. The data are reasonably well fit by the full form of the binding isotherm equation. Table 4 summarizes the dissociation constant ($K_d$) values for the interaction of the five aptamer candidates with HE4-GST. All four aptamers selected on the basis of enrichment during selection displayed some affinity for HE4-GST by one or both methods. The sequence D3 chosen from the earliest selection round (R2) displayed the lowest affinity in the anisotropy assay, and no detectable interaction by affinity probe capillary electrophoresis (APCE), suggesting that two selection rounds would not have been sufficient to select a high-affinity aptamer for this particular target. The negative control aptamer, L1, displays discrepant affinity binding, with essentially no binding displayed in the fluorescence anisotropy assay and moderate affinity displayed in the APCE assay. We are currently investigating the cause of this discrepant binding behavior. In a previous study using CE-SELEX and high-throughput sequencing to identify aptamers for rhVEGF$_{165}$, affinity CE and fluorescence anisotropy were used to determine $K_d$ values [23], yielding estimates of $K_d$ that differed by up to a factor of 7.3 between the two methods. With the exception of the behavior of L1, our two affinity characterization methods agree to an extent comparable to that seen by other investigators in this area. We also tested the affinity of all five sequences for binding to GST by APCE. All five aptamers tested displayed no affinity for GST, with no positive trend in ratioed peak heights over a concentration range of GST from 0 to 250 nM (data not shown). The negative rounds of selection—in which aptamer candidates displaying affinity for the free GST affinity tag were purged from the DNA pool—seem to have been successful, as indicated by these results.

In conclusion, we have demonstrated the proof of concept for using capillary-based aptamer selection, high-throughput sequencing, and a freely available bioinformatics pipeline to select DNA aptamers with affinity for ovarian cancer biomarker HE4. The validity of this combination has also been demonstrated by another very recent publication in this journal [31]. Our current efforts focus on improving the PCR process to reduce the formation of by-products using emulsion PCR [32] and using a six-histidine-modified HE4 as the target protein in place of the more sterically hindered HE4-GST, with the goal of selecting higher affinity aptamers than those reported here. Aptamers with high binding affinity, reflected by low nanomolar $K_d$ values, are sought for use in bioassays and in eventual clinical application. Inclusion of divalent cations in the selection buffer is also hypothesized to enable greater diversity of secondary structure and therefore greater binding affinity; selection in such a buffer is also in progress.

Acknowledgments The project described was supported by Grant Number R15CA161970 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. Financial support from a Henry Dreyfus Teacher Scholar Award (to RJW) is gratefully acknowledged. The authors wish to thank Marie Adams, Jeff Nie, Jan Hoinka, and Teresa Przytycka for stimulating discussions.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. American Cancer Society (2014) Cancer facts & figures 2014
2. Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, Hassell L, Baldwin RL, Karlan BY, Hood L (1999) Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 238:375–385
3. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ, Morin PJ (2000) Large-scale serial analysis of gene expression reveals genes differently expressed in ovarian cancer. Cancer Res 60:6281–6287
4. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellström KE
Selection of DNA aptamers for ovarian cancer biomarker HE4

(2003) The HE4 (WFDC2) protein is a biomarker for ovarian cancer. Cancer Res 63:3695–3700

5. Rosen DG, Wang L, Atkinson JW, Yu Y, Lu KH, Diamandis EP, Hellström I, Mok CS, Liu J, Bast RC Jr (2005) Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99:267–277

6. Dragkin R, van Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL (2005) Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65:2162–2169

7. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr (2008) The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108:402–408

8. Moore RG, McMeehn DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ (2009) A novel multiple marker bioassay utilizing HE4 and CA125 for prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112:40–46

9. Anderson GL, McIntosh M, Goodman G, Thorpe JD, Bergan L, Thomquist MD, Scholler N, Kim N, O’Briant K, Drescher C, Urban N (2010) Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 102:26–36

10. Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346:818–822

11. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505–510

12. Tombelli S, Minunni M, Mascini M (2005) Analytical applications of aptamers. Biosens Bioelectron 20:2424–2434

13. Anderson GL, McIntosh M, Goodman G, Thorpe JD, Bergan L, Thomquist MD, Scholler N, Kim N, O’Briant K, Drescher C, Urban N (2010) Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 102:26–36

14. Mairal T, Özalp VC, Sánchez PL, Mir M, Katakis I, O’Brian K, Drescher C, Urban N (2010) Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 102:26–36

15. Gopinath SCB (2007) Methods developed for SELEX. Anal Bioanal Chem 390:171–182

16. Szeitner Z, András J, Gyurcsányi RE, Mészáros T (2014) Is less better? Lessons from aptamer selection strategies. J Pharm Biomed Anal 101:58–65

17. Mendoza SD, Bowser MT (2004) In vitro selection of functional DNA using capillary electrophoresis. J Am Chem Soc 126:20–21

18. Berezovski M, Drabovich A, Krylova SM, Musheev M, Okhoun V, Petrov A, Krylova SN (2005) Nonequilibrium capillary electrophoresis of equilibrium mixtures: a universal tool for development of aptamers. J Am Chem Soc 127:3165–3171

19. Mendonsa SD, Bowser MT (2004) In vitro selection of high-affinity DNA ligands for human IgE using capillary electrophoresis. Anal Chem 76:5387–5392

20. Cho M, Yao Y, Nie J, Stewart R, Csordas AT, Oh SS, Thomson JA, Soh HT (2010) Quantitative selection of DNA aptamers through microfluidic selection and high-throughput sequencing. Proc Natl Acad Sci 107:15373–15378

21. Mards ER (2008) The impact of next-generation sequencing technology on genetics. Trends Genet 24:133–141

22. Mards ER (2011) A decade’s perspective on DNA sequencing technology. Nature 470:198–203

23. Jing M, Bowser MT (2013) Tracking the emergence of high affinity aptamers for rhVEGF165 during capillary electrophoresis-systematic evolution of ligands by exponential enrichment using high throughput sequencing. Anal Chem 85:10761–10770

24. Schütze T, Wilhelm B, Greiner J, Peter F, Mörl M, Erdmann VA, Lehrach H, Kontur Z, Menger M, Arndt PF, Glikler J (2011) Probing the SELEX process with next-generation sequencing. PLoS ONE 6:e29604

25. Hoon S, Zhou B, Janda KD, Brenner S, Scolnick J (2011) Aptamer selection by high-throughput sequencing and informatic analysis. BioTechniques 51:413–416

26. Musheev MU, Krylov SN (2006) Selection of aptamers by systematic evolution of ligands by exponential enrichment: addressing the polymerase chain reaction issue. Anal Chim Acta 564:91–96

27. Thiel WH, Bair T, Peek AS, Liu X, Dassie J, Stockdale KR, Behlke MA, Miller FJ, Giangrande PH (2012) Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection. PLoS ONE 7:e43836

28. Hoinka J, Berezkozy A, Sauna ZE, Gilboa E, Przytycka TM (2014) AptaCluster—a method to cluster HT-SELEX aptamer pools and lessons from its application. In: Sharan R (ed) RECOMB 2014. Springer International, Switzerland

29. Jiang P, Meyer S, Hou Z, Propson NE, Soh HT, Thomson JA, Stewart R (2014) MPBind: a Meta-motif-based statistical framework and pipeline to Predict Binding potential of SELEX-derived aptamers. Bioinformatics 30:2665–2667

30. Li W, Godzik A (2006) Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics 22:1658–1659. doi:10.1093/bioinformatics/btl158

31. Riley KR, Gagliano J, Xiao J, Libby K, Saito S, Yu G, Cubicciotti R, Macosko J, Colyer CL, Guthold M, Bonin K (2015) Combining capillary electrophoresis and next-generation sequencing for aptamer selection. Anal Bioanal Chem 407:1527–1532

32. Yufa R, Krylova SM, Bruce C, Bag B, Schofield C, Krylov SN (2015) Emulsion PCR significantly improves nonequilibrium capillary electrophoresis of equilibrium mixtures-based aptamer selection: allowing for efficient and rapid selection of aptamer to unmodified ABH2 protein. Anal Chem 87:1411–1419